NEOS Neo Therapeutics Inc

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference

DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference.

The presentation will be available for on-demand viewing on the Investor Relations page of the company’s website at beginning Monday, January 11, 2021 at 6:00 a.m. ET. A replay of the webcast will be available on Neos’ website for 30 days.

About Neos Therapeutics

Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company developing and manufacturing central nervous system (CNS)-focused products. Neos markets Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD. Neos also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions. Additional information about Neos is available at .

CONTACTS:

Richard I. Eisenstadt

Chief Financial Officer

Neos Therapeutics

(972) 408-1389

 

Sarah McCabe

Investor Relations

Stern Investor Relations, Inc.

(212) 362-1200



EN
04/01/2021

Underlying

NEOSNeo Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neo Therapeutics Inc

 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neo...

Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at , or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help ...

March 12, 2021 1 EN
 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeuti...

Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at , or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders...

March 10, 2021 1 EN
 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Sto...

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 – Record date for each Special Meeting of Stockholders is February 5, 2021 – – Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. – ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage ph...

February 10, 2021 1 EN
 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Con...

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available for on-demand viewing on the Investor Relations page of the company’s website...

January 4, 2021 1 EN
 PRESS RELEASE
Free
NEOS Neo Therapeutic...

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agree...

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022  Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class prescription therapeutic...

December 10, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch